Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Intensity Therapeutics Inc (NASDAQ: INTS) was $0.41 for the day, down -1.75% from the previous closing price of $0.42. In other words, the price has decreased by -$1.75 from its previous closing price. On the day, 0.8 million shares were traded. INTS stock price reached its highest trading level at $0.4254 during the session, while it also had its lowest trading level at $0.402.
Ratios:
Our analysis of INTS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.60. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INTS now has a Market Capitalization of 24650662 and an Enterprise Value of 17701662.
Stock Price History:
The Beta on a monthly basis for INTS is 4.15, which has changed by -0.79049563 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, INTS has reached a high of $3.17, while it has fallen to a 52-week low of $0.19. The 50-Day Moving Average of the stock is -3.16%, while the 200-Day Moving Average is calculated to be -36.15%.
Shares Statistics:
INTS traded an average of 30.33M shares per day over the past three months and 3234230 shares per day over the past ten days. A total of 60.06M shares are outstanding, with a floating share count of 54.81M. Insiders hold about 8.76% of the company’s shares, while institutions hold 6.99% stake in the company. Shares short for INTS as of 1764288000 were 2507610 with a Short Ratio of 0.08, compared to 1761868800 on 16769283. Therefore, it implies a Short% of Shares Outstanding of 2507610 and a Short% of Float of 4.33.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Intensity Therapeutics Inc (INTS) in the stock market.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.32 and -$0.37 for the fiscal current year, implying an average EPS of -$0.34. EPS for the following year is -$0.22, with 2.0 analysts recommending between -$0.19 and -$0.25.
